期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
Both APRI and FIB‐4 could effectively evaluate liver fibrosis in liver transplantation recipients 被引量:1
1
作者 Xiao‐han Fang Man Xie +6 位作者 Youwei Zhao Qun Zhang Qiu‐ju Tian Liu Zhao Hong Liu Wei Rao xinjuan kong 《Portal Hypertension & Cirrhosis》 2022年第3期197-199,共3页
To the Editor,Liver transplantation(LT)is the only curative therapy for patients with end‐stage liver disease.1 Due to the high incidence of metabolic syndrome after LT,nonalcoholic fatty liver disease(NAFLD)has grad... To the Editor,Liver transplantation(LT)is the only curative therapy for patients with end‐stage liver disease.1 Due to the high incidence of metabolic syndrome after LT,nonalcoholic fatty liver disease(NAFLD)has gradually become an essential cause of post‐LT fibrosis.2 Liver fibrosis can progress to liver cirrhosis and carries the risk of developing hepatocellular carcinoma(HCC),which adversely affects long‐term survival after LT.3,4 Early detection and active intervention for liver fibrosis after LT are crucial in LT recipients.Previous studies have confirmed that transient elastography(TE)could accurately detect liver fibrosis in LT recipients by comparing TE with liver biopsy. 展开更多
关键词 liver CURATIVE NAFLD
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部